Editorial
Copyright ©2012 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Cardiol. Nov 26, 2012; 4(11): 302-308
Published online Nov 26, 2012. doi: 10.4330/wjc.v4.i11.302
Anti-oxidized low-density lipoprotein antibodies in chronic heart failure
Gideon Charach, Alexander Rabinovich, Ori Argov, Moshe Weintraub, Lior Charach, Oded Ayzenberg, Jacob George
Gideon Charach, Alexander Rabinovich, Ori Argov, Moshe Weintraub, Lior Charach, Departments of Internal Medicine “C”, Tel Aviv Sourasky Medical Center, 6 Weizman Street, Tel Aviv 64239, Israel
Oded Ayzenberg, Jacob George, Departments of Cardiology, Kaplan Medical Center, Rehovot 76100, Israel
Author contributions: Charach G prepared and wrote the review; Rabinovich A, Argov O, Weintraub M and Ayzenberg O contributed by supervising and analyzing the data; Charach L technically supported the work; and George J prepared and wrote the paper.
Correspondence to: Gideon Charach, MD, Departments of Internal Medicine “C”, Tel Aviv Sourasky Medical Center, 6 Weizman Street, Tel Aviv 64239, Israel. drcharach@012.net.il
Telephone: +972-524-266851 Fax: +972-3-6974990
Received: July 18, 2012
Revised: September 13, 2012
Accepted: September 20, 2012
Published online: November 26, 2012
Abstract

Oxidative stress may play a significant role in the pathogenesis of heart failure (HF). Antibodies to oxidized low-density lipoprotein (oxLDL Abs) reflect an immune response to LDL over a prolonged period and may represent long-term oxidative stress in HF. The oxLDL plasma level is a useful predictor of mortality in HF patients, and measurement of the oxLDL Abs level may allow better management of those patients. Antibodies to oxLDL also significantly correlate with the New York Heart Association score. Hypercholesterolemia, smoking, hypertension, and obesity are risk factors for atherosclerotic coronary heart disease (CHD) leading to HF, but these factors account for only one-half of all cases, and understanding of the pathologic process underlying HF remains incomplete. Nutrients with antioxidant properties can reduce the susceptibility of LDL to oxidation. Antioxidant therapy may be an adjunct to lipid-lowering, angiotensin converting enzyme inhibition and metformin (in diabetes) therapy for the greatest impact on CHD and HF. Observational data suggest a protective effect of antioxidant supplementation on the incidence of HD. This review summarizes the data on oxLDL Abs as a predictor of morbidity and mortality in HF patients.

Keywords: Heart failure, Oxidized low-density lipoproteins, Antibodies, Antioxidants